Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.10), Zacks reports.
Lakewood-Amedex Biotherapeutics Price Performance
NASDAQ:LABT traded down $0.06 during trading hours on Monday, hitting $0.22. 828,332 shares of the stock were exchanged, compared to its average volume of 7,485,027. The company’s 50 day moving average is $0.99. Lakewood-Amedex Biotherapeutics has a twelve month low of $0.17 and a twelve month high of $98.20. The firm has a market capitalization of $519,978.00 and a P/E ratio of -0.05.
Analyst Upgrades and Downgrades
LABT has been the topic of a number of recent analyst reports. Wall Street Zen lowered Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. Weiss Ratings upgraded Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. Finally, HC Wainwright initiated coverage on Lakewood-Amedex Biotherapeutics in a research note on Wednesday, October 28th. They issued a “buy” rating for the company. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold”.
Get Our Latest Stock Report on Lakewood-Amedex Biotherapeutics
About Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.
Featured Stories
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
